FILINGS
| GSK 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2026-05-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-05-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2026-05-01 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2026-04-29 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-29 | 6-K | 1ST QUARTER RESULTS | View Document |
| 2026-04-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-28 | 6-K | BEPIROVIRSEN PRIORITY REVIEW US FILING ACCEPTANCE | View Document |
| 2026-04-27 | 6-K | EFIMOSFERMIN GRANTED US/EU REGULATORY DESIGNATIONS | View Document |
| 2026-04-27 | 6-K | TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION | View Document |
| 2026-04-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-23 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-22 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-21 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-20 | 6-K | BLENREP APPROVED IN CHINA FOR 2L+ MULTIPLE MYELOMA | View Document |
| 2026-04-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-15 | 6-K | GSK COMPLETES ACQUISITION OF 35PHARMA INC. | View Document |
| 2026-04-15 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-14 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-13 | 6-K | GSK PRESENTS POSITIVE DATA FOR BEHOLD 1 B7 H4 ADC | View Document |
| 2026-04-13 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-10 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-09 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-08 | 6-K | EXDENSUR APPROVED FOR CRSWNP IN CHINA | View Document |
| 2026-04-08 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-07 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-02 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2026-04-01 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-04-01 | 6-K | VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDING | View Document |
| 2026-03-31 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-30 | 6-K | BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA | View Document |
| 2026-03-30 | 6-K | EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA | View Document |
| 2026-03-30 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-27 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-27 | 6-K | BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA | View Document |
| 2026-03-26 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-03-25 | 6-K | NOTICE OF AGM | View Document |
| 2026-03-25 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-24 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-03-23 | 6-K | ADMISSION TO TRADING | View Document |
| 2026-03-23 | 6-K | GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS | View Document |
| 2026-03-23 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-19 | 6-K | LYNAVOY (LINERIXIBAT) APPROVED BY US FDA | View Document |
| 2026-03-19 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-03-18 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-03-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-13 | 6-K | US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR | View Document |
| 2026-03-13 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-03-12 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-11 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-10 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-09 | 6-K | BOARD COMMITTEE CHANGE | View Document |
| 2026-03-09 | 6-K | GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS | View Document |
| 2026-03-09 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-06 | 6-K | FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F | View Document |
| 2026-03-06 | IRANNOTICE | IRANNOTICE | View Document |
| 2026-03-06 | 20-F | 20-F | View Document |
| 2026-03-06 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-05 | 6-K | GSK PUBLISHES ANNUAL REPORT 2025 | View Document |
| 2026-03-05 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-04 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-03-04 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-03 | 6-K | GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS | View Document |
| 2026-03-03 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-03 | SC TO-T/A | SC TO-T/A | View Document |
| 2026-03-02 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-03-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2026-02-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-02-27 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-02-26 | 6-K | LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA | View Document |
| 2026-02-26 | 6-K | BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW | View Document |
| 2026-02-26 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-02-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-02-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-02-25 | 6-K | GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA | View Document |
| 2026-02-25 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-02-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-02-24 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-02-24 | SC TO-T/A | SC TO-T/A | View Document |
| 2026-02-23 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-02-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-02-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2026-02-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-02-19 | 6-K | TRANSACTION IN OWN SHARES | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.